-
1 Comment
Financière de Tubize SA is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 1468.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1000000.0.
Financière de Tubize SA's total revenue sank by 5.1% to $131M since the same quarter in the previous year.
Its net income has dropped by 5.0% to $130M since the same quarter in the previous year.
Finally, its free cash flow fell by 182.4% to $-761K since the same quarter in the previous year.
Based on the above factors, Financière de Tubize SA gets an overall score of 1/5.
| Exchange | BR |
|---|---|
| CurrencyCode | EUR |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | BE0003823409 |
| Market Cap | 5B |
|---|---|
| PE Ratio | 57.34 |
| Dividend Yield | 0.8% |
| Beta | 0.43 |
| Target Price | 182.75 |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affects immune system or central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TUB.BR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
